1,8-cineole

1,8-cineole at a Glance

1,8-Cineole — eucalyptol — is the dominant oxygenated monoterpene of eucalyptus oil, and the compound responsible for the sharp, cooling smell of eucalyptus, rosemary and bay.

Unusually for a plant terpene, the isolated molecule has real clinical evidence. Standardised 200 mg cineole capsules have been through double-blind randomised trials in COPD, asthma, bronchitis and rhinosinusitis — so the human data here describes the actual molecule at a defined dose, rather than an essential oil or a whole-plant extract.

That makes it one of the better-evidenced single terpenes here, and it is why its respiratory uses read differently from most aromatherapy claims.

What It's Used For

1,8-Cineole (eucalyptol) is a bicyclic monoterpenoid ether — the fresh, camphoraceous principal of eucalyptus oil and a major volatile of rosemary, cardamom, sage and bay. It stands out among plant terpenes for one reason: unlike most essential-oil constituents, whose human evidence is aromatherapy or whole-oil, cineole has genuine double-blind, placebo-controlled trials of the isolated molecule — standardized 200 mg gut-soluble capsules (marketed as “Cineole”/Soledum) tested in COPD, asthma, acute bronchitis and rhinosinusitis ^{1,2,3,4,5Reference 1Worth H et al. · 2009RCTConcomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trialView study →Reference 2Juergens UR et al. · 2003RCTAnti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial — randomised controlled trialView study →Reference 3Worth H · 2012RCTPatients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial — randomised controlled trialView study →Reference 4Kehrl W et al. · 2004RCTTherapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trialView study →Reference 5Fischer J · 2013RCTEfficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial — randomised controlled trialView study →}.

Mechanistically it behaves as a mucolytic and anti-inflammatory, suppressing cytokine and arachidonic-acid-mediator production in human immune cells ^{6,7Reference 6Juergens UR et al. · 1998Antiinflammatory effects of eucalyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivoView study →Reference 7Juergens UR et al. · 2004In vitroInhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes — in vitroView study →}.

Two caveats frame the rest: the respiratory trials cluster around a small set of overlapping investigators, and pharmacokinetically cineole is both a CYP3A substrate and an inducer of hepatic drug-metabolizing P450s — an interaction-relevant profile, and the same molecule that makes concentrated eucalyptus oil neurotoxic when swallowed in bulk ^{8,11,12Reference 8Cai ZM et al. · 2021ReviewCai ZM, Peng JQ, Chen Y, Tao L, Zhang YY, Fu LY, Long QD, Shen XC. (2021). 1,8-Cineole: a review of source, biological activities, and application — review. Journal of Asian Natural Products Research, 23(10), 938–954. https://pubmed.ncbi.nlm.nih.gov/33111547/View study →Reference 11Miyazawa M et al. · 2001AnimalOxidation of 1,8-cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomesView study →Reference 12Jori A et al. · 1972On the inducing activity of eucalyptol — animal studyView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume, tempered for isolate-vs-plant match and bioavailability. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links to its write-up.

01COPD (exacerbation reduction)Promising72%Isolated-cineole double-blind RCT, n=242, 6 months ^{1Reference 1Worth H et al. · 2009RCTConcomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trialView study →}

02Asthma (steroid-sparing)Promising64%Two isolated-cineole double-blind RCTs incl. prednisolone-sparing ^{2,3Reference 2Juergens UR et al. · 2003RCTAnti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial — randomised controlled trialView study →Reference 3Worth H · 2012RCTPatients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial — randomised controlled trialView study →}

03Acute bronchitisPromising56%Isolated-cineole double-blind RCT, n=242 ^{5Reference 5Fischer J · 2013RCTEfficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial — randomised controlled trialView study →}

04Acute rhinosinusitisPromising54%Isolated-cineole double-blind RCT, n=152 ^{4Reference 4Kehrl W et al. · 2004RCTTherapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trialView study →}

05AntimicrobialShaky34%In-vitro / whole-oil; membrane disruption ^{8,16Reference 8Cai ZM et al. · 2021ReviewCai ZM, Peng JQ, Chen Y, Tao L, Zhang YY, Fu LY, Long QD, Shen XC. (2021). 1,8-Cineole: a review of source, biological activities, and application — review. Journal of Asian Natural Products Research, 23(10), 938–954. https://pubmed.ncbi.nlm.nih.gov/33111547/View study →Reference 16Sataie-Mokhtari T et al. · 2026In vitroGC-MS based chemical composition and in vitro antibacterial activity of the essential oils of Eucalyptus cultivarsView study →}

06Cognition & alertnessShaky28%Human aroma-exposure correlation (plant EO) ^{14Reference 14Moss M · 2012Clinical trialPlasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma — human studyView study →}

Mechanisms

Pharmacokinetics

Cineole’s pharmacokinetics are the compound page’s core value-add, and they carry the interaction story. It is well absorbed: during human inhalation it reaches peak plasma at about 18 minutes, with a rapid distribution half-life (~6.7 min) and a terminal elimination half-life around 104 minutes ^{9Reference 9Jäger W et al. · 1996Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation — human pharmacokinetic studyView study →}. Given orally (studied via sage tea), it is rapidly and extensively hydroxylated by cytochrome P450 to 2-, 3-, 7- and 9-hydroxy-1,8-cineole and then glucuronidated; the parent compound stays at low plasma concentration while 2-hydroxycineole predominates, and roughly half the dose is recovered in urine as hydroxycineole metabolites within 10 hours ^{10Reference 10Horst K · 2010Quantification of 1,8-cineole and of its metabolites in humans using stable isotope dilution assays — human pharmacokinetic studyView study →}. Human liver microsome work identifies CYP3A as a principal oxidizer of cineole ^{11Reference 11Miyazawa M et al. · 2001AnimalOxidation of 1,8-cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomesView study →}. The interaction-relevant twist is that cineole is not only a CYP substrate but a CYP inducer: it up-regulates hepatic drug-metabolizing P450s in classic and later animal studies ^{12,13Reference 12Jori A et al. · 1972On the inducing activity of eucalyptol — animal studyView study →Reference 13Madyastha KM · 1986AnimalMetabolism of 1,8-cineole in rat: its effects on liver and lung microsomal cytochrome P-450 systems — animal studyView study →}, so co-administration could, in principle, accelerate the clearance of Cyp-metabolized drugs. Human enzyme-induction data are limited, so this is a mechanism-based caution rather than a quantified clinical interaction.

Clinical trials

Unusually for a plant terpene, several investigator-led double-blind RCTs of the isolated molecule have been completed — all respiratory (COPD, asthma, acute bronchitis, rhinosinusitis) and largely from an overlapping German research network — but as an off-patent natural product it attracts little registered industry-sponsored trial activity.

Last checked: July 2026.

Isolate vs. Plant Studies

Cineole is the rare essential-oil constituent whose human evidence is mostly the isolated molecule, not a plant standing in for it. The COPD, asthma, bronchitis and rhinosinusitis trials all used standardized 200 mg cineole capsules (“Cineole”/Soledum), so their results genuinely describe the compound rather than a eucalyptus preparation ^{1,2,3,4,5Reference 1Worth H et al. · 2009RCTConcomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trialView study →Reference 2Juergens UR et al. · 2003RCTAnti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial — randomised controlled trialView study →Reference 3Worth H · 2012RCTPatients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial — randomised controlled trialView study →Reference 4Kehrl W et al. · 2004RCTTherapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trialView study →Reference 5Fischer J · 2013RCTEfficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial — randomised controlled trialView study →} — a real strength, and the reason cineole rates higher here than sibling terpenes like α-pinene whose human data are inhalation pharmacokinetics only. The mechanistic monocyte/lymphocyte work is likewise on isolated cineole ^{6,7Reference 6Juergens UR et al. · 1998Antiinflammatory effects of eucalyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivoView study →Reference 7Juergens UR et al. · 2004In vitroInhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes — in vitroView study →}. The main plant-vehicle exception is the cognition finding, where the exposure was whole rosemary aroma and cineole was measured as a correlate, not administered alone ^{14Reference 14Moss M · 2012Clinical trialPlasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma — human studyView study →}; and the antimicrobial literature is largely whole eucalyptus oil ^{16Reference 16Sataie-Mokhtari T et al. · 2026In vitroGC-MS based chemical composition and in vitro antibacterial activity of the essential oils of Eucalyptus cultivarsView study →}. The whole-plant relationship also runs the other way: the expectorant reputation of rosemary, peppermint, hyssop and yerba santa is often attributed to cineole, but those oils are chemically complex, so a whole-oil effect cannot be pinned on cineole alone.

Prevalence in Nature

1,8-Cineole is one of the most widespread oxygenated monoterpenes in the plant kingdom, produced across the Myrtaceae (Eucalyptus, Melaleuca/tea tree), Lamiaceae (rosemary, sage, lavender, hyssop, catnip), Asteraceae (yarrow, wormwood), Zingiberaceae (cardamom) and Lauraceae (bay, rosewood) ^{8Reference 8Cai ZM et al. · 2021ReviewCai ZM, Peng JQ, Chen Y, Tao L, Zhang YY, Fu LY, Long QD, Shen XC. (2021). 1,8-Cineole: a review of source, biological activities, and application — review. Journal of Asian Natural Products Research, 23(10), 938–954. https://pubmed.ncbi.nlm.nih.gov/33111547/View study →}. Its marquee — and namesake — source is Eucalyptus: in Eucalyptus globulus leaf oil cineole is the dominant compound, measured at around 83.5% of the essential oil, and pharmaceutical-grade eucalyptus oil is standardized to a high cineole content ^{16Reference 16Sataie-Mokhtari T et al. · 2026In vitroGC-MS based chemical composition and in vitro antibacterial activity of the essential oils of Eucalyptus cultivarsView study →}. It is also the defining marker of the rosemary “cineole chemotype” (roughly 15–55% of the oil, occasionally higher) ^{17Reference 17Satyal P et al. · 2017Chemotypic characterization and biological activity of Rosmarinus officinalisView study →}, a major oxygenated monoterpenoid of cardamom seed oil (~25–31%) ^{18Reference 18Wanna R et al. · 2024Chemical compositions and fumigation effects of essential oils derived from cardamom (Elettaria cardamomum) and galangal (Alpinia galanga)View study →}, and a consistent minor-to-moderate component of sage (~9–11%) ^{19Reference 19Milenković L et al. · 2025Does photoselective netting influence yield, chemical composition and antioxidant activities of essential oils in cultivated sage? Frontiers in Plant Science, 16, 1540520. https://pubmed.ncbi.nlm.nih.gov/40365559/View study →} and peppermint (~3.5–14%) ^{21Reference 21European PharmacopoeiaReviewPeppermint oil (Menthae piperitae aetheroleum) monograph — gas-chromatographic composition limits, 1,8-cineole 3.5–14.0%}.

Concentration is dominated by chemotype and plant part rather than species alone: rosemary occurs as cineole-, camphor- and verbenone-dominant chemotypes that are chemically distinct oils ^{17Reference 17Satyal P et al. · 2017Chemotypic characterization and biological activity of Rosmarinus officinalisView study →}, and in true lavender cineole is normally minor — elevated levels flag adulteration with spike lavender or lavandin. Biosynthetically, cineole is a plastidial monoterpene formed from geranyl diphosphate: a 1,8-cineole synthase cyclizes the universal monoterpene precursor to the bicyclic ether in a single enzymatic step, and the enzyme’s abundance and specificity are what make some oils cineole-rich. Cineole is essentially a plant (and to a lesser extent fungal) product, with no established animal biosynthesis.

Discovery & Synthesis

1,8-Cineole was characterized from eucalyptus oil in the nineteenth century, and the common name “eucalyptol” — reflecting its source rather than its structure — is generally attributed to French chemistry of around 1870; the precise first-isolation date is not cleanly pinned in the modern literature (see the gaps note). Today the molecule is essentially never made by total synthesis for commercial use: it is obtained by fractional distillation and rectification of eucalyptus oil (chiefly from Eucalyptus globulus and high-cineole species such as E. polybractea), which is so rich in cineole that fractionation to pharmaceutical grade (and the standardized capsules used in the clinical trials) is far cheaper than synthesis ^{8,16Reference 8Cai ZM et al. · 2021ReviewCai ZM, Peng JQ, Chen Y, Tao L, Zhang YY, Fu LY, Long QD, Shen XC. (2021). 1,8-Cineole: a review of source, biological activities, and application — review. Journal of Asian Natural Products Research, 23(10), 938–954. https://pubmed.ncbi.nlm.nih.gov/33111547/View study →Reference 16Sataie-Mokhtari T et al. · 2026In vitroGC-MS based chemical composition and in vitro antibacterial activity of the essential oils of Eucalyptus cultivarsView study →}. Cineole-rich oils from rosemary, cardamom and Melaleuca are secondary natural sources.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

At the isolated therapeutic dose used in trials (200 mg three times daily), cineole was well tolerated, with adverse events comparable to placebo and only mild effects such as heartburn reported ^{1,4Reference 1Worth H et al. · 2009RCTConcomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trialView study →Reference 4Kehrl W et al. · 2004RCTTherapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trialView study →}. The safety concern is dose- and preparation-dependent, and it is an isolate-vs-plant story in reverse: cineole is the principal toxic constituent of concentrated eucalyptus oil, and ingestion of eucalyptus oil in bulk causes dose-dependent central-nervous-system toxicity — drowsiness, ataxia, vomiting and, at higher doses, seizures. This is well described in children, in whom depressed consciousness and seizures are the classic picture, and even adults who swallow large amounts can present with seizures and severe metabolic acidosis ^{15Reference 15Ittyachen AM et al. · 2019Case reportEucalyptus oil poisoning: two case reports — case reportView study →}. The practical rule that follows is longstanding: cineole-rich (eucalyptus-type) oils should never be applied on or near the face or nostrils of infants and very young children, where they can trigger laryngospasm or reflex apnea, and concentrated oils should be kept out of reach and never taken neat.

The interaction profile is the second load-bearing point. Cineole is a substrate of CYP3A and an inducer of hepatic drug-metabolizing cytochrome P450s ^{11,12,13Reference 11Miyazawa M et al. · 2001AnimalOxidation of 1,8-cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomesView study →Reference 12Jori A et al. · 1972On the inducing activity of eucalyptol — animal studyView study →Reference 13Madyastha KM · 1986AnimalMetabolism of 1,8-cineole in rat: its effects on liver and lung microsomal cytochrome P-450 systems — animal studyView study →}; mechanistically this means cineole (or cineole-rich preparations taken regularly) could lower plasma levels of drugs cleared by these enzymes, though human interaction data are limited and the effect has not been quantified clinically. No formal maximum tolerated dose of the isolate is established beyond the trial ceiling of ~600 mg/day. Reproductive and developmental toxicity of isolated cineole in humans has not been well characterized; this is a scope limitation, not an all-clear.

Dosage

Across the double-blind trials the studied regimen is consistent: 200 mg of cineole three times daily (gut-soluble capsules), given as add-on therapy in COPD and asthma ^{1,2,3Reference 1Worth H et al. · 2009RCTConcomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trialView study →Reference 2Juergens UR et al. · 2003RCTAnti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial — randomised controlled trialView study →Reference 3Worth H · 2012RCTPatients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial — randomised controlled trialView study →} and as monotherapy in acute bronchitis ^{5Reference 5Fischer J · 2013RCTEfficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial — randomised controlled trialView study →}; the rhinosinusitis trial used 100 mg twice per capsule intake, three times daily (≈600 mg/day) ^{4Reference 4Kehrl W et al. · 2004RCTTherapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trialView study →}.

These are doses studied in research and are not a personal recommendation — appropriateness depends on the individual, their other medications (see the CYP interactions above) and professional guidance; concentrated eucalyptus/cineole oils are not a substitute for the standardized capsules and carry the ingestion hazards described above.

References

1. Worth H, Schacher C, Dethlefsen U. (2009). Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial — randomised controlled trial. Respiratory Research, 10, 69. https://pubmed.ncbi.nlm.nih.gov/19624838/
2. Juergens UR, Dethlefsen U, Steinkamp G, Gillissen A, Repges R, Vetter H. (2003). Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial — randomised controlled trial. Respiratory Medicine, 97(3), 250–256. https://pubmed.ncbi.nlm.nih.gov/12645832/
3. Worth H, Dethlefsen U. (2012). Patients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial — randomised controlled trial. Journal of Asthma, 49(8), 849–853. https://pubmed.ncbi.nlm.nih.gov/22978309/
4. Kehrl W, Sonnemann U, Dethlefsen U. (2004). Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial — randomised controlled trial. The Laryngoscope, 114(4), 738–742. https://pubmed.ncbi.nlm.nih.gov/15064633/
5. Fischer J, Dethlefsen U. (2013). Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial — randomised controlled trial. Cough, 9(1), 25. https://pubmed.ncbi.nlm.nih.gov/24261680/
6. Juergens UR, Stöber M, Schmidt-Schilling L, Kleuver T, Vetter H. (1998). Antiinflammatory effects of eucalyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo. European Journal of Medical Research, 3(9), 407–412. https://pubmed.ncbi.nlm.nih.gov/9737886/
7. Juergens UR, Engelen T, Racké K, Stöber M, Gillissen A, Vetter H. (2004). Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes — in vitro. Pulmonary Pharmacology & Therapeutics, 17(5), 281–287. https://pubmed.ncbi.nlm.nih.gov/15477123/
8. Cai ZM, Peng JQ, Chen Y, Tao L, Zhang YY, Fu LY, Long QD, Shen XC. (2021). 1,8-Cineole: a review of source, biological activities, and application — review. Journal of Asian Natural Products Research, 23(10), 938–954. https://pubmed.ncbi.nlm.nih.gov/33111547/
9. Jäger W, Nasel B, Nasel C, Binder R, Stimpfl T, Vycudilik W, Buchbauer G. (1996). Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation — human pharmacokinetic study. Chemical Senses, 21(4), 477–480. https://pubmed.ncbi.nlm.nih.gov/8866111/
10. Horst K, Rychlik M. (2010). Quantification of 1,8-cineole and of its metabolites in humans using stable isotope dilution assays — human pharmacokinetic study. Molecular Nutrition & Food Research, 54(10), 1515–1529. https://pubmed.ncbi.nlm.nih.gov/20425757/
11. Miyazawa M, Shindo M, Shimada T. (2001). Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes. Drug Metabolism and Disposition, 29(2), 200–205. https://pubmed.ncbi.nlm.nih.gov/11159812/
12. Jori A, Di Salle E, Pescador R. (1972). On the inducing activity of eucalyptol — animal study. Journal of Pharmacy and Pharmacology, 24(6), 646–649. https://pubmed.ncbi.nlm.nih.gov/4404435/
13. Madyastha KM, Chadha A. (1986). Metabolism of 1,8-cineole in rat: its effects on liver and lung microsomal cytochrome P-450 systems — animal study. Bulletin of Environmental Contamination and Toxicology, 37(5), 759–766. https://pubmed.ncbi.nlm.nih.gov/3779163/
14. Moss M, Oliver L. (2012). Plasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma — human study. Therapeutic Advances in Psychopharmacology, 2(3), 103–113. https://pubmed.ncbi.nlm.nih.gov/23983963/
15. Ittyachen AM, George GR, Radhakrishnan M, Joy Y. (2019). Eucalyptus oil poisoning: two case reports — case report. Journal of Medical Case Reports, 13(1), 326. https://pubmed.ncbi.nlm.nih.gov/31685016/
16. Sataie-Mokhtari T, et al. (2026). GC-MS based chemical composition and in vitro antibacterial activity of the essential oils of Eucalyptus cultivars. Scientific Reports, 16. https://pubmed.ncbi.nlm.nih.gov/42436153/
17. Satyal P, Jones TH, Lopez EM, McFeeters RL, Ali NAA, Mansi I, Al-Kaf AG, Setzer WN. (2017). Chemotypic characterization and biological activity of Rosmarinus officinalis. Foods, 6(3), 20. https://pubmed.ncbi.nlm.nih.gov/28273883/
18. Wanna R, et al. (2024). Chemical compositions and fumigation effects of essential oils derived from cardamom (Elettaria cardamomum) and galangal (Alpinia galanga). Plants, 13(13), 1848. https://pubmed.ncbi.nlm.nih.gov/38999684/
19. Milenković L, Ilić ZS, Stanojević L, Šunić L, Milenković A, Stanojević J, Cvetković D. (2025). Does photoselective netting influence yield, chemical composition and antioxidant activities of essential oils in cultivated sage? Frontiers in Plant Science, 16, 1540520. https://pubmed.ncbi.nlm.nih.gov/40365559/
20. Joshi RK. (2013). Volatile composition and antimicrobial activity of the essential oil of Artemisia absinthium growing in the Western Ghats region of North West Karnataka, India. Pharmaceutical Biology, 51(7), 888–892. https://pubmed.ncbi.nlm.nih.gov/23570523/
21. European Pharmacopoeia. Peppermint oil (Menthae piperitae aetheroleum) monograph — gas-chromatographic composition limits, 1,8-cineole 3.5–14.0%. European Directorate for the Quality of Medicines & HealthCare (EDQM).

View all 21 references▾